New research and treatment options for acute myeloid leukemia.
Miller
C B
CB
D000208:Acute Disease; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000906:Antibodies / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004337:Drug Carriers; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D000069283:Rituximab; D014481:United States
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D004337:Drug Carriers; D000922:Immunotoxins; D000069283:Rituximab; D000079982:Gemtuzumab